Bionovo, a clinical stage drug discovery and development company, has announced that its drug candidate for metastatic breast cancer, BZL101, will advance to Phase II clinical testing after the successful completion of a second Phase I clinical trial.

Bionovo has reported positive results from two independent physician surveys, which showed that MF101 could become first-line treatment for menopausal vasomotor symptoms or hot flashes.

Bionovo has initiated a phase I/II trial of its drug candidate for the treatment of women with advanced breast cancer. The aims of the current phase I/II trial are to determine the maximum tolerated dose of the drug candidate BZL101 and tumor response in women with late stage breast cancer.

Bionovo said Wednesday it was cleared to start a U.S. phase 2 trial of MF101, a new treatment for menopausal symptoms.